
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
Research Point Global and WuXi Clinical Development Services have announced that they will rebrand as WuXi Clinical at DIA 2019 in San Diego, CA. The newly combined CRO specializes in collaborative partnering for global clinical trials, and prides itself in its extremely patient-centric approaches.
For mor informaton click







